• Who we are
    • ABOUT MEDICINES FOR EUROPE
    • PURPOSE AND OBJECTIVES
    • OUR VALUES – OUR 5 PILLARS
    • STRUCTURE
    • MEMBERS
    • BECOME A MEMBER
    • CODE OF CONDUCT
    • DISCLOSURE
    • Vacancies
  • PRIORITIES
  • Key topics
    • ACCESS
    • INDUSTRIAL POLICY
    • REGULATORY AND LEGAL FRAMEWORK
    • FALSIFIED MEDICINES
    • SUSTAINABILITY
    • ANTIMICROBIAL RESISTANCE
    • MEDICINE SHORTAGES
  • Publications
    • EXTERNAL RESOURCES
    • FACTSHEETS
    • INFOGRAPHICS
    • PODCAST
    • POLICY
    • REPORTS
    • VIDEOS
  • Newsroom
    • IN THE NEWS
    • PRESS RELEASES
  • Contact us
Login Login
Medicines for Europe
  • Generic medicines
    • Home
    • Medicines for Europe
      • Generic medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • Definition
      • THERAPEUTIC AREAS
      • GLOSSARY
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Related links
      • Contact us
    • Twitter
  • Biosimilar medicines
    • Home
    • Medicines for Europe
      • Biosimilar medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • DEFINITION
      • THERAPEUTIC AREAS
      • GLOSSARY
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
      • External resources
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Related links
      • Contact us
    • Twitter
  • Value added medicines
    • Home
    • Who we are
      • Value added medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • Definition
      • THERAPEUTIC AREAS
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Contact us
  • Events

How can your healthcare system support a wider access to Value Added Medicines?

27 May 2019

Related Posts

  • Reformed incentives system promises better patient access in… 11 June 2024 A well-balanced incentives system for pharmaceuticals is essential to support…
  • European Parliament lends its support to a fair cost-based… 30 June 2023 The EU pharmaceutical strategy aims to improve accessibility, affordability and…
  • Generic medicines: 70% of dispensed medicines and critical… 10 April 2024 For the last three decades, the availability of cost-effective generic…
  • One- Pager: New pricing models for generic medicines 10 October 2022 How can we ensure a sustainable healthcare system while safeguarding…
Medicines for Europe
MEMBER OF
IGBA EMVO
  • Contact us
  • Privacy Policy
Medicines for Europe AISBL
Rue d’Arlon 50
1000 Brussels Belgium
T : +32 (0)2 736 84 11
Powered by Big Smile Agency
Medicines For Europe
  • Who we are
  • Vacancies
  • PRIORITIES
  • Key topics – COVID-19
  • Publications
  • Newsroom
  • Contact us
  • SECTOR GROUPS
    • Generic medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
      • FIND OUT MORE
    • Biosimilar medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
      • FIND OUT MORE
    • Value added medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
  • Events
 Share This
 LinkedIn

Share on Mastodon

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok